Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study

BACKGROUND: Crohn's disease (CD) and multiple sclerosis (MS) share common pathogenic processes. Interferon (IFN) beta-1a is effective and generally well tolerated in patients with MS and has been shown to down-regulate the expression of interleukin-12, a cytokine that is thought to be involved...

Descripción completa

Detalles Bibliográficos
Autores principales: Pena Rossi, Claudia, Hanauer, Stephen B, Tomasevic, Ratko, Hunter, John O, Shafran, Ira, Graffner, Hans
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674451/
https://www.ncbi.nlm.nih.gov/pubmed/19302707
http://dx.doi.org/10.1186/1471-230X-9-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674451/
https://www.ncbi.nlm.nih.gov/pubmed/19302707
http://dx.doi.org/10.1186/1471-230X-9-22

Ejemplares similares